Immune‑transcriptomic correlates of response to alpha‑ versus beta‑emitting PRRT in neuroendocrine tumors

/in , /by

Peptide receptor radionuclide therapy (PRRT) is being used more often to treat certain solid tumors, such as neuroendocrine tumors that express somatostatin receptors and some prostate cancers. One form of PRRT uses a beta‑emitting drug (177Lu‑DOTATATE), which is currently the standard treatment for many of these neuroendocrine tumors. Another, newer approach uses an alpha‑emitting drug […]

Read more

ASTX295 + Olaparib: A Targeted Strategy for BRCA2‑Mutant, TP53‑Wild‑Type Cancers

/in /by

ASTX295 is an experimental cancer drug that works by turning on a powerful tumor‑suppressor protein called p53 in cancer cells that still have a normal version of the gene TP53. In many cancers, p53 is not broken but is kept switched off by another protein called MDM2, which constantly tags p53 for destruction. ASTX295 blocks […]

Read more

How exercise protects the prostate: a new CNTF pathway that calms tumor‑supporting cells and boosts immune attack

/in /by

We know that exercise can help reduce the risk of getting prostate cancer and may slow its progression, but exactly how this happens inside the body has remained unclear. A recent study in mice has now uncovered an important new mechanism that links physical exercise to the way tumors behave and how the immune system […]

Read more

MUC1‑C Targeting with XYA02‑8‑ADC, for Castration‑Resistant and Neuroendocrine Prostate Cancer

/in , /by

In advanced prostate cancer, castration‑resistant and neuroendocrine variants present some of the toughest clinical challenges because they often lose dependence on androgen receptor signaling and become refractory to hormone‑targeted therapies. Within this resistant landscape, MUC1‑C, the C‑terminal subunit of the mucin‑1 oncoprotein, emerges as a promising alternative target. MUC1‑C is aberrantly overexpressed and under‑glycosylated in […]

Read more

JZY‑2233: A PSMA‑Targeted Degrader‑Antibody Conjugate for Advanced Prostate Cancer

/in , /by

Researchers have developed a new targeted therapy for advanced prostate cancer called JZY‑2233, a degrader‑antibody conjugate that homes in on prostate‑specific membrane antigen (PSMA) while delivering a highly potent CBP/p300 degrader directly to tumor cells. CBP and p300 are transcriptional coactivators that help the androgen receptor drive oncogenic gene programs in prostate cancer, and small‑molecule […]

Read more

NEOK001: A New Bispecific Antibody–Drug Conjugate for Advanced Prostate Cancer

/in , /by

A promising new experimental drug called NEOK001 (also known as ABL206) is emerging as a potential therapy for advanced cancers that express two specific proteins on their surface: B7‑H3 and ROR1. Among these cancers, prostate cancer is one of the tumor types where early data already show signs of activity, making NEOK001 a candidate of […]

Read more

Healthy Eating After Prostate Cancer Tied to Lower Risk of Frailty

/in /by

Eating a healthier diet after a prostate cancer diagnosis may help men age with more strength and resilience, according to a large prospective observational U.S. study that will be presented at the AACR 2026 meeting. The analysis followed more than five thousand men from the Health Professionals Follow‑up Study who were not frail when they […]

Read more

Higher Vitamin D Levels Before Diagnosis Linked to Better Prostate Cancer Survival

/in /by

A large international pooled analysis of over twelve thousand men with prostate cancer adds substantial evidence that men who have higher circulating levels of vitamin D before their diagnosis tend to live longer after developing the disease. The study, which will be presented at AACR Annual Meeting 2026, focused on 25‑hydroxyvitamin D, the major blood […]

Read more